Lord, Abbett & Co. LLC Vertex Pharmaceuticals Inc Transaction History

Lord, Abbett & Co. LLC

$29.9 Billion
Q2 2024

A detailed history of Lord, Abbett & Co. LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 2,979 shares of VRTX stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,979

Previous 124,263 97.6%

Holding current value

$1.45 Million

Previous $51.9 Million 97.31%

% of portfolio

0.0%

Previous 0.17%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $47.6 Million - $58.9 Million	-121,284 Reduced 97.6%	2,979 $1.4 Million
Q1 2024 May 09, 2024	SELL	$407.69 - $446.08 $942,579 - $1.03 Million	-2,312 Reduced 1.83%	124,263 $51.9 Million
Q4 2023 Feb 12, 2024	SELL	$343.0 - $410.68 $35.1 Million - $42 Million	-102,187 Reduced 44.67%	126,575 $51.5 Million
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $610,753 - $654,602	-1,806 Reduced 0.78%	228,762 $79.6 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $12.6 Million - $14.1 Million	39,970 Added 20.97%	230,568 $81.1 Million
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $54.8 Million - $62.5 Million	-193,389 Reduced 50.36%	190,598 $60.1 Million
Q4 2022 Feb 10, 2023	SELL	$285.76 - $321.48 $48.8 Million - $54.8 Million	-170,599 Reduced 30.76%	383,987 $111 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $5.95 Million - $6.64 Million	21,734 Added 4.08%	554,586 $161 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $26 Million - $32.3 Million	-110,555 Reduced 17.18%	532,852 $150 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $142 Million - $168 Million	643,407 New	643,407 $168 Million
Q3 2021 Nov 09, 2021	SELL	$181.39 - $202.99 $21.5 Million - $24.1 Million	-118,676 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$187.49 - $221.1 $1.26 Million - $1.49 Million	-6,729 Reduced 5.37%	118,676 $23.9 Million
Q1 2021 May 11, 2021	SELL	$207.02 - $241.31 $26.5 Million - $30.9 Million	-128,154 Reduced 50.54%	125,405 $26.9 Million
Q4 2020 Feb 09, 2021	SELL	$207.01 - $276.09 $35 Million - $46.7 Million	-169,012 Reduced 40.0%	253,559 $59.9 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $1.55 Million - $1.84 Million	6,069 Added 1.46%	422,571 $115 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $21.3 Million - $28 Million	-94,657 Reduced 18.52%	416,502 $121 Million
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $31.7 Million - $39.4 Million	158,833 Added 45.08%	511,159 $122 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $23.1 Million - $31.1 Million	138,762 Added 64.97%	352,326 $77.1 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $1.3 Million - $1.47 Million	-7,849 Reduced 3.54%	213,564 $36.2 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $28.8 Million - $33.3 Million	-174,935 Reduced 44.14%	221,413 $40.6 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $6.58 Million - $7.82 Million	-40,184 Reduced 9.21%	396,348 $72.9 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $142,187 - $179,908	-936 Reduced 0.21%	436,532 $72.3 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $13.1 Million - $15 Million	78,060 Added 21.72%	437,468 $84.3 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $23 Million - $26.8 Million	-157,720 Reduced 30.5%	359,408 $61.1 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $11.3 Million - $13.2 Million	74,795 Added 16.91%	517,128 $84.3 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $32.4 Million - $36.7 Million	-236,025 Reduced 34.79%	442,333 $66.3 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $32.5 Million - $35.6 Million	219,299 Added 47.77%	678,358 $103 Million
Q2 2017 Aug 14, 2017	BUY	N/A	459,059	459,059 $59.2 Million

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $125B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Account

Lord, Abbett & Co. LLC Vertex Pharmaceuticals Inc Transaction History